SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.62
−0.88%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 3.75x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 44.67x
- Price / sales
- 4.78x
- Price / cash flow
- -2.85x
Enterprise value
- Enterprise value
- $586.7M
- EV / sales
- 5.02x
- EV / EBITDA
- -2.83x
- EV / EBIT
- -2.71x
- Market cap
- $558.9M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026